Results 11 to 20 of about 9,804 (228)

Characterizations of HCV NS5A replication complex inhibitors

Virology, 2013
The hepatitis C virus NS5A protein is an established and clinically validated target for antiviral intervention by small molecules. Characterizations are presented of compounds identified as potent inhibitors of HCV replication to provide insight into structural elements that interact with the NS5A protein.
O'Boyle II, Donald R., Sun, Jin-Hua, Nower, Peter T., Lemm, Julie A., Fridell, Robert A., Wang, Chunfu, Romine, Jeffrey L., Belema, Makonen, Nguyen, Van N., Laurent, Denis R. St., Serrano-Wu, Michael, Snyder, Lawrence B., Meanwell, Nicholas A., Langley, David R., Gao, Min   +14 more
openaire   +4 more sources

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source

Preclinical Pharmacokinetics and First-in-Human Pharmacokinetics, Safety, and Tolerability of Velpatasvir, a Pangenotypic Hepatitis C Virus NS5A Inhibitor, in Healthy Subjects. [PDF]

Antimicrob Agents Chemother, 2017
Mogalian E, German P, Kearney BP, Yang CY, Brainard D, Link J, McNally J, Han L, Ling J, Mathias A.   +9 more
europepmc   +2 more sources

Inhibitors of NS5A for Treatment of HCV Infection [PDF]

ACS Medicinal Chemistry Letters, 2013
Inhibitors of NS5A for Treatment of HCV Infection Jean-Francois Brazeau and Gerard Rosse* Structure Guided Chemistry, Dart Neuroscience LLC, 7473 Lusk Boulevard, San Diego, California 92121, United States Adjunct Associate Professor, Department of Pharmacology and Physiology, College of Medicine, Drexel University, New College Building, 245 North 15th ...
Jean-Francois, Brazeau, Gerard, Rosse
openaire   +2 more sources

Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance

Hepatology Communications, 2020
Direct acting antivirals (DAAs) have revolutionized hepatitis C virus (HCV) treatment, but drug resistance could undermine proposed global elimination targets.
Mark W. Douglas, Enoch S.E. Tay, Dao Sen Wang, Adrian T.L. Ong, Caroline Wilson, Amy Phu, Jen Kok, Dominic E. Dwyer, Rowena A. Bull, Andrew R. Lloyd, Tanya L. Applegate, Gregory J. Dore, Anita Y. Howe, Richard Harrigan, Jacob George   +14 more
doaj   +1 more source

Synthesis and evaluation of non-dimeric HCV NS5A inhibitors [PDF]

Bioorganic & Medicinal Chemistry Letters, 2013
Based on the symmetrical bidentate structure of the NS5A inhibitor BMS-790052, a series of new monodentate molecules were designed. The synthesis of 36 new non-dimeric NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system. Among them compound 5a showed picomolar range activity along with an excellent
Franck, Amblard, Hongwang, Zhang, Longhu, Zhou, Junxing, Shi, Drew R, Bobeck, James H, Nettles, Satish, Chavre, Tamara R, McBrayer, Philip, Tharnish, Tony, Whitaker, Steven J, Coats, Raymond F, Schinazi   +11 more
openaire   +2 more sources

Resistance Analysis of a 3-Day Monotherapy Study with Glecaprevir or Pibrentasvir in Patients with Chronic Hepatitis C Virus Genotype 1 Infection

Viruses, 2018
Glecaprevir (an NS3/4A protease inhibitor) and pibrentasvir (an NS5A inhibitor) are potent and pangenotypic hepatitis C virus (HCV) direct-acting antivirals.
Teresa I. Ng, Tami Pilot-Matias, Rakesh Tripathi, Gretja Schnell, Preethi Krishnan, Thomas Reisch, Jill Beyer, Tatyana Dekhtyar, Michelle Irvin, Liangjun Lu, Armen Asatryan, Andrew Campbell, Betty Yao, Sandra Lovell, Federico Mensa, Eric J. Lawitz, Jens Kort, Christine Collins   +17 more
doaj   +1 more source

Synthesis and evaluation of novel potent HCV NS5A inhibitors [PDF]

Bioorganic & Medicinal Chemistry Letters, 2012
Judicious modifications to the structure of the previously reported HCV NS5A inhibitor 1, resulted in more potent anti-HCV compounds with similar and in some cases improved toxicity profiles. The synthesis of 19 new NS5A inhibitors is reported along with their ability to block HCV replication in an HCV 1b replicon system.
Hongwang, Zhang, Longhu, Zhou, Franck, Amblard, Junxing, Shi, Drew R, Bobeck, Sijia, Tao, Tamara R, McBrayer, Phillip M, Tharnish, Tony, Whitaker, Steven J, Coats, Raymond F, Schinazi   +10 more
openaire   +2 more sources

Resistance Patterns Associated with HCV NS5A Inhibitors Provide Limited Insight into Drug Binding

Viruses, 2014
Direct-acting antivirals (DAAs) have significantly improved the treatment of infection with the hepatitis C virus. A promising class of novel antiviral agents targets the HCV NS5A protein.
Moheshwarnath Issur, Matthias Götte
doaj   +1 more source

Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.

PLoS ONE, 2020
BackgroundL31 and Y93 in the NS5A region of the hepatitis C virus (HCV) are the most important substitution positions associated with resistance to direct-acting antiviral (DAA) treatment.MethodsWe analyzed the frequency of NS5A L31M/V and Y93/H in NS5A ...
Naoki Morishita, Ryotaro Sakamori, Tomomi Yamada, Yugo Kai, Yuki Tahata, Ayako Urabe, Ryoko Yamada, Takahiro Kodama, Hayato Hikita, Yoshinori Doi, Shinji Tamura, Hideki Hagiwara, Yasuharu Imai, Sadaharu Iio, Tomohide Tatsumi, Tetsuo Takehara   +15 more
doaj   +1 more source